GlassScriptPhysician profile
Jay L Lafleur
NPI 1245488824
$24,693.45
in general payments reported to CMS, 2019-2025
55 companies · $6,718 in 2025
The $6,718 reported for 2025 was more than what 93% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,295 · 2020: $973 · 2021: $8,280 · 2022: $2,049 · 2023: $779 · 2024: $2,600 · 2025: $6,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,088 · Food and Beverage: $3,602 · Travel and Lodging: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,087.50 |
| Food and Beverage | $3,601.95 |
| Travel and Lodging | $1,406.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $6,299.36 | 2023-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Nalu Medical, INC. | $5,864.59 | 2021-2025 | Nalu Neurostimulation System |
| Vertiflex, INC. | $2,215.85 | 2019 | |
| Relievant Medsystems, INC. | $852.11 | 2021-2023 | Intracept |
| Spinal Simplicity, LLC | $834.17 | 2022 | |
| Abbvie INC. | $794.52 | 2021-2025 | |
| Abbott Laboratories | $759.74 | 2019-2023 | Proclaim, Axium |
| Collegium Pharmaceutical, INC. | $718.86 | 2019-2025 | Xtampza, Belbuca |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $688.79 | 2019-2025 | Relistor, Trulance |
| Si-Bone, INC. | $677.34 | 2024 | |
| Painteq LLC | $557.66 | 2022-2025 | Painteq |
| Medtronic, INC. | $548.17 | 2021-2025 | Intellis Adaptivestim, V-Loc 180 |
| Boston Scientific Corporation | $391.64 | 2019-2022 | |
| Grt US Holding, INC. | $374.55 | 2020-2022 | |
| Nevro Corp. | $268.03 | 2021-2024 | Senza |
Show all 54 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Lafleur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.